CEL-SCI Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

CEL-SCI şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-47.9%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-47.9%
Gelecekteki Temettü Verimi	n/a
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: CVM şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: CVM şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

CEL-SCI Piyasaya Karşı Temettü Getirisi

CVM temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (CVM)	n/a
Pazarın Alt %25'i (US)	1.4%
Pazarın En İyi %25'i (US)	4.2%
Sektör Ortalaması (Biotechs)	2.3%
Analist tahmini (CVM) (3 yıla kadar)	n/a

Önemli Temettü: CVM şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, CVM şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: CVM şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: CVM herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

CEL-SCI Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

CEL-SCI Corporation Names Patricia B. Prichep as Chief Financial Officer

CEL-SCI Corporation Names Patricia B. Prichep as Chief Financial Officer

U.S. FDA and CEL-SCI Corporation Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence First Quarter 2025

CEL-SCI Corporation Reports New Data from Its Concluded Phase 3 Study of Multikine® (Leukocyte Interleukin, Injection)

The UK’s Medicines & Healthcare Products Regulatory Agency Grants CEL-SCI Corporation A Pediatric Waiver, Bringing Multikine One Step Closer to Future Marketing Clearance

CEL-SCI Corporation has completed a Follow-on Equity Offering in the amount of $10.7737 million.

CEL-SCI Corporation has filed a Follow-on Equity Offering in the amount of $10.845 million.

CEL-SCI Corporation Announces Phase 3 Population Analysis for Upcoming Confirmatory Registration Study in Head & Neck Cancer

CEL-SCI Corporation Appoints Robert Watson as Chairperson of the Board

CEL-SCI Corporation(NYSEAM:CVM) dropped from Russell 3000E Value Index

New major risk - Financial position

CEL-SCI Corporation Announces Significantly Positive Outcome from its Recent Meeting with U.S. Food and Drug Administration Regarding Path to Approval for its First-Line Investigational Cancer Immunotherapy Multikine

Less than half of directors are independent

No longer forecast to breakeven

New minor risk - Market cap size

CEL-SCI Corporation, Annual General Meeting, Apr 19, 2024

CEL-SCI Corporation has filed a Follow-on Equity Offering in the amount of $7.75 million.

CEL-SCI Corporation has completed a Follow-on Equity Offering in the amount of $4.98 million.

CEL-SCI Corporation has filed a Follow-on Equity Offering in the amount of $4.98 million.

CEL-SCI Corporation has filed a Follow-on Equity Offering in the amount of $4.98 million.

CEL-Sci Corporation Releases Video Detailing Recent Phase 3 Findings & Its Plans to Seek Immediate Regulatory Approvals

CEL-SCI Presents the Data for the First Time at the European Society for Medical Oncology Congress in Spain

New major risk - Share price stability

Cel-Sci Files Request with the Uk's Mhra Regarding Path to Approval for Multikine in the Treatment of Head & Neck Cancer

Cel-Sci Submits Scientific Advice Filing to European Medicines Agency (Ema) for Multikine in the Treatment of Head & Neck Cancer

CEL-SCI Corporation Reports Phase 3 Tumor PD-L1 Biomarker Data Demonstrate Multikine’s Increased Efficacy and Points to Potential for Combination with Checkpoint Inhibitors for Head & Neck Cancer

New minor risk - Market cap size

CEL-SCI Corporation to Present Novel Data at AHNS 11th International Conference on Head and Neck Cancer--New Patent to Be Filed

CEL-SCI Corporation to Present Novel Data at AHNS 11th International Conference on Head and Neck Cancer--New Patent to Be Filed

CEL-SCI Corporation Announces Latest Results from Its Pivotal Phase 3 Study of Multikine

No longer forecast to breakeven

Forecast breakeven date moved forward to 2023

Price target decreased by 23% to US$11.50

Consensus revenue estimates fall by 33%

Forecast breakeven date pushed back to 2024

Price target increased to US$15.00

Forecast breakeven date pushed back to 2024

CEL-SCI Corporation Announces Phase 3 Multikine® Head and Neck Cancer Results

CEL-SCI Corporation Appoints Gail Naughton to its Board of Directors

CEL-SCI Corporation(NYSEAM:CVM) dropped from Russell 3000E Growth Index

CEL-SCI Corporation, Annual General Meeting, Jun 13, 2022

Price target increased to US$15.00

Insufficient new directors

Chief Scientific Officer recently sold US$169k worth of stock

Price target decreased to US$12.00

Forecast breakeven pushed back to 2023

Market Sentiment Around Loss-Making CEL-SCI Corporation (NYSEMKT:CVM)

Insider recently sold US$244k worth of stock

We Think CEL-SCI (NYSEMKT:CVM) Can Afford To Drive Business Growth

New 90-day high: US$26.54

What Does CEL-SCI's (NYSEMKT:CVM) CEO Pay Reveal?

Earnings beat expectations, revenue disappoints

Full year 2020 earnings released: US$0.82 loss per share

Breakeven On The Horizon For CEL-SCI Corporation (NYSEMKT:CVM)

CEL-SCI’s LEAPS Peptides Demonstrate Clear Survival Benefit as A Treatment for COVID-19 in Preclinical Studies

Insider notifies of intention to sell stock

Insider recently sold US$127k worth of stock

New 90-day low: US$11.56

New 90-day high: US$14.51

Analysts update estimates

Third quarter earnings released

New 90-day low - US$12.04

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin